In addition, multiple secondary outcomes including HFE, new systolic heart failure, atrial arrhythmias, and new-onset AKI were also lower in the tirzepatide group; and 3) tirzepatide was associated with a greater improvement in several biomarkers such as HbA1c, LDL, triglycerides, and albumin:creatinine ratio compared to GLP-1RA. This evidence concerns the gene ALB and systolic heart failure.